Future therapeutic approaches for inflammatory bowel diseases

Gastroenterology

Volumn 140, Issue 6, 2011, Pages 1838-1846

  Plevy, Scott E ^a,c   Targan, Stephan R ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Biomarkers; IBD Immunology; IBD Therapy

Indexed keywords

ABATACEPT; ADALIMUMAB; ALICAFORSEN; ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER; CCR9 ANTAGONIST; CERTOLIZUMAB PEGOL; CYCLOSPORIN A; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 17 ANTIBODY; INTERLEUKIN 23 ANTIBODY; INTERLEUKIN 6 INHIBITOR; LYSYLPROLYLVALINE; MONOCLONAL ANTIBODY ALPHA4BETA7; MONOCLONAL ANTIBODY BETA7; MONOCLONAL ANTIBODY MUCOSAL ADDRESSIN CELL ADHESION MOLECULE; NATALIZUMAB; PLACEBO; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; VEDOLIZUMAB;

ARTICLE; CELL THERAPY; COLITIS; CROHN DISEASE; DRUG MECHANISM; DRUG TARGETING; ENTERITIS; GENETIC ASSOCIATION; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNITY; MESENCHYMAL STEM CELL; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT OUTCOME; ULCERATIVE COLITIS;

EID: 79955550194     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2011.02.014     Document Type: Article

References (62)

1. D. Rachmilewitz New forms of treatment for inflammatory bowel disease Gut 33 1992 1301 1302
2. S.H. Murch, V.A. Lamkin, and M.O. Savage Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease Gut 32 1991 913 917
3. C. Stevens, G. Walz, and C. Singaram Tumor necrosis factor-α, interleukin-1 β, and interleukin-6 expression in inflammatory bowel disease Dig Dis Sci 37 1992 818 826
4. F. Powrie, M.W. Leach, and S. Mauze Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells Immunity 1 1994 553 562
5. M.F. Neurath, I. Fuss, and M. Pasparakis Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice Eur J Immunol 27 1997 1743 1750 (Pubitemid 27302858)
6. J.E. de Vries Immunosuppressive and anti-inflammatory properties of interleukin 10 Ann Med 27 1995 537 541
7. D.M. Rennick, and M.M. Fort Lessons from genetically engineered animal models XII. IL-10-deficient (IL-10(-/-) mice and intestinal inflammation Am J Physiol Gastrointest Liver Physiol 278 2000 G829 G833
8. R.N. Fedorak, A. Gangl, and C.O. Elson Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group Gastroenterology 119 2000 1473 1482 (Pubitemid 32198672)
9. S. Schreiber, R.N. Fedorak, and O.H. Nielsen Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease Crohn's Disease IL-10 Cooperative Study Group Gastroenterology 119 2000 1461 1472 (Pubitemid 32198671)
10. H. Tilg, C. van Montfrans, and A. van den Ende Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon γ Gut 50 2002 191 195 (Pubitemid 34087930)
11. E.O. Glocker, D. Kotlarz, and K. Boztug Inflammatory bowel disease and mutations affecting the interleukin-10 receptor N Engl J Med 361 2009 2033 2045
12. S. Lichtiger, D.H. Present, and A. Kornbluth Cyclosporine in severe ulcerative colitis refractory to steroid therapy N Engl J Med 330 1994 1841 1845 (Pubitemid 24188135)
13. M.C. Genovese, J.C. Becker, and M. Schiff Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition N Engl J Med 353 2005 1114 1123 (Pubitemid 41317434)
14. L.M. Amezcua-Guerra, B. Hernandez-Martinez, and C. Pineda Ulcerative colitis during CTLA-4Ig therapy in a patient with rheumatoid arthritis Gut 55 2006 1059 1060 (Pubitemid 43962637)
15. Q. Tang, K.J. Henriksen, and E.K. Boden Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells J Immunol 171 2003 3348 3352 (Pubitemid 37254533)
16. Q. Tang, and J.A. Bluestone The Foxp3+ regulatory T cell: a jack of all trades, master of regulation Nat Immunol 9 2008 239 244 (Pubitemid 351267321)
17. M.J. Barnes, and F. Powrie Regulatory T cells reinforce intestinal homeostasis Immunity 31 2009 401 411
18. G. Monteleone, L. Biancone, and R. Marasco Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells Gastroenterology 112 1997 1169 1178 (Pubitemid 27157528)
19. I.J. Fuss, M. Neurath, and M. Boirivant Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease Crohn's disease LP cells manifest increased secretion of IFN-γ, whereas ulcerative colitis LP cells manifest increased secretion of IL-5 J Immunol 157 1996 1261 1270 (Pubitemid 126449643)
20. L.E. Harrington, P.R. Mangan, and C.T. Weaver Expanding the effector CD4 T-cell repertoire: the Th17 lineage Curr Opin Immunol 18 2006 349 356
21. S.Z. Sheikh, K. Matsuoka, and T. Kobayashi Cutting edge: IFN-γ is a negative regulator of IL-23 in murine macrophages and experimental colitis J Immunol 184 2010 4069 4073
22. O. Stuve, R. Gold, and A. Chan α4-Integrin antagonism with natalizumab: effects and adverse effects J Neurol 255 Suppl 6 2008 58 65
23. K.R. Carson, D. Focosi, and E.O. Major Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) Project Lancet Oncol 10 2009 816 824
24. B.G. Feagan, G.R. Greenberg, and G. Wild Treatment of active Crohn's disease with MLN0002, a humanized antibody to the α4β7 integrin Clin Gastroenterol Hepatol 6 2008 1370 1377
25. B.G. Feagan, G.R. Greenberg, and G. Wild Treatment of ulcerative colitis with a humanized antibody to the α4β7 integrin N Engl J Med 352 2005 2499 2507 (Pubitemid 41007865)
26. L. Steidler, W. Hans, and L. Schotte Treatment of murine colitis by Lactococcus lactis secreting interleukin-10 Science 289 2000 1352 1355 (Pubitemid 30656052)
27. H. Braat, P. Rottiers, and D.W. Hommes A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease Clin Gastroenterol Hepatol 4 2006 754 759 (Pubitemid 43841860)
28. J.O. Lindsay, C.J. Ciesielski, and T. Scheinin Local delivery of adenoviral vectors encoding murine interleukin 10 induces colonic interleukin 10 production and is therapeutic for murine colitis Gut 52 2003 981 987 (Pubitemid 36765290)
29. H. Laroui, G. Dalmasso, and H.T. Nguyen Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model Gastroenterology 138 2010 843 853 e1-2
30. S.J. van Deventer, M.K. Wedel, and B.F. Baker A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis Aliment Pharmacol Ther 23 2006 1415 1425
31. D.S. Wilson, G. Dalmasso, and L. Wang Orally delivered thioketal nanoparticles loaded with TNF-α-siRNA target inflammation and inhibit gene expression in the intestines Nat Mater 9 2010 923 928
32. D.W. van Bekkum Experimental basis of hematopoietic stem cell transplantation for treatment of autoimmune diseases J Leukoc Biol 72 2002 609 620 (Pubitemid 36277830)
33. T.M. Brusko, A.L. Putnam, and J.A. Bluestone Human regulatory T cells: role in autoimmune disease and therapeutic opportunities Immunol Rev 223 2008 371 390 (Pubitemid 351986182)
34. A.W. Thomson, and P.D. Robbins Tolerogenic dendritic cells for autoimmune disease and transplantation Ann Rheum Dis 67 Suppl 3 2008 iii90 iii96
35. A. Uccelli, G. Mancardi, and S. Chiesa Is there a role for mesenchymal stem cells in autoimmune diseases? Autoimmunity 41 2008 592 595
36. G.Y. Melmed, and S.R. Targan Future biologic targets for IBD: potentials and pitfalls Nat Rev Gastroenterol Hepatol 7 2010 110 117
37. S.R. Targan, B.G. Feagan, and R.N. Fedorak Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial Gastroenterology 132 2007 1672 1683 (Pubitemid 46695722)
38. S.R. Targan Challenges in IBD research America CsaCFo, ed 1st ed. 1989 Crohn's and Colitis Foundation of America New York 18
39. D.Q. Shih, and S.R. Targan Insights into IBD pathogenesis Curr Gastroenterol Rep 11 2009 473 480
40. D. Yen, J. Cheung, and H. Scheerens IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6 J Clin Invest 116 2006 1310 1316
41. A. Gottlieb, A. Menter, and A. Mendelsohn Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial Lancet 373 2009 633 640
42. K.A. Papp, R.G. Langley, and M. Lebwohl Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2) Lancet 371 2008 1675 1684 (Pubitemid 351671884)
43. C.L. Leonardi, A.B. Kimball, and K.A. Papp Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) Lancet 371 2008 1665 1674 (Pubitemid 351671883)
44. W.J. Sandborn, B.G. Feagan, and R.N. Fedorak A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease Gastroenterology 135 2008 1130 1141
45. R. Panaccione, W. Sandborn, and G. Gordon Briakinumab (anti-interleukin 12/23p40, ABT874) for treatment of Crohn's disease Am J Gastroenterol 105 2010 S1245
46. J.C. Barrett, S. Hansoul, and D.L. Nicolae Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease Nat Genet 40 2008 955 962
47. A. Franke, D.P. McGovern, and J.C. Barrett Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci Nat Genet 42 2010 1118 1125
48. K.D. Taylor, S.R. Targan, and L. Mei IL23R haplotypes provide a large population attributable risk for Crohn's disease Inflamm Bowel Dis 14 2008 1185 1191
49. T. Haritunians, K.D. Taylor, and S.R. Targan Genetic predictors of medically refractory ulcerative colitis Inflamm Bowel Dis 16 2010 1830 1840
50. W.S. Mow, E.A. Vasiliauskas, and Y.C. Lin Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease Gastroenterology 126 2004 414 424 (Pubitemid 38182298)
51. I.D. Arnott, C.J. Landers, and E.J. Nimmo Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype Am J Gastroenterol 99 2004 2376 2384 (Pubitemid 40039369)
52. K.A. Papadakis, H. Yang, and A. Ippoliti Anti-flagellin (CBir1) phenotypic and genetic Crohn's disease associations Inflamm Bowel Dis 13 2007 524 530 (Pubitemid 46799635)
53. M.C. Dubinsky, S. Kugathasan, and L. Mei Increased immune reactivity predicts aggressive complicating Crohn's disease in children Clin Gastroenterol Hepatol 6 2008 1105 1111
54. F. Seibold, S. Brandwein, and S. Simpson pANCA represents a cross-reactivity to enteric bacterial antigens J Clin Immunol 18 1998 153 160 (Pubitemid 28120182)
55. P. Fleshner, A. Ippoliti, and M. Dubinsky Both preoperative perinuclear antineutrophil cytoplasmic antibody and anti-CBir1 expression in ulcerative colitis patients influence pouchitis development after ileal pouch-anal anastomosis Clin Gastroenterol Hepatol 6 2008 561 568
56. E. Slack, S. Hapfelmeier, and B. Stecher Innate and adaptive immunity cooperate flexibly to maintain host-microbiota mutualism Science 325 2009 617 620
57. M.C. Dubinsky, L. Mei, and M. Friedman Genome wide association (GWA) predictors of anti-TNFα therapeutic responsiveness in pediatric inflammatory bowel disease Inflamm Bowel Dis 16 2010 1357 1366
58. I. Arijs, K. Li, and G. Toedter Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis Gut 58 2009 1612 1619
59. K. Yamazaki, D. McGovern, and J. Ragoussis Single nucleotide polymorphisms in TNFSF15 confer susceptibility to Crohn's disease Hum Mol Genet 14 2005 3499 3506 (Pubitemid 41672132)
60. K.S. Michelsen, L.S. Thomas, and K.D. Taylor IBD-associated TL1A gene (TNFSF15) haplotypes determine increased expression of TL1A protein PLoS One 4 2009 e4719
61. H. Takedatsu, K.S. Michelsen, and B. Wei TL1A (TNFSF15) regulates the development of chronic colitis by modulating both T-helper 1 and T-helper 17 activation Gastroenterology 135 2008 552 567
62. Y. Picornell, L. Mei, and K. Taylor TNFSF15 is an ethnic-specific IBD gene Inflamm Bowel Dis 13 2007 1333 1338 (Pubitemid 350206842)